Satellos Financial Statements From 2010 to 2025
| MSCLF Stock | USD 0.53 0.05 10.42% |
Check Satellos Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Satellos Bioscience's main balance sheet or income statement drivers, such as , as well as many indicators such as . Satellos financial statements analysis is a perfect complement when working with Satellos Bioscience Valuation or Volatility modules.
Satellos |
Satellos Bioscience OTC Stock Return On Asset Analysis
Satellos Bioscience's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Satellos Bioscience Return On Asset | -0.4 |
Most of Satellos Bioscience's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Satellos Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Satellos Bioscience has a Return On Asset of -0.3953. This is 95.48% lower than that of the Healthcare sector and 98.32% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 182.36% higher than that of the company.
Satellos Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Satellos Bioscience's current stock value. Our valuation model uses many indicators to compare Satellos Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Satellos Bioscience competition to find correlations between indicators driving Satellos Bioscience's intrinsic value. More Info.Satellos Bioscience is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Satellos Bioscience's earnings, one of the primary drivers of an investment's value.About Satellos Bioscience Financial Statements
Satellos Bioscience stakeholders use historical fundamental indicators, such as Satellos Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Satellos Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Satellos Bioscience's assets and liabilities are reflected in the revenues and expenses on Satellos Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Satellos Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Satellos Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Satellos OTC Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.